Glenn Noronha News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Glenn noronha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Glenn Noronha Today - Breaking & Trending Today

PYC Therapeutics Assembles Ophthalmology-Focused Clinical Advisory Board

PYC Therapeutics Assembles Ophthalmology-Focused Clinical Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Stanford University , United Kingdom , Western Australia , San Diego , University College , New South Wales , City Of , San Francisco , Mark Pennesi , Santa Barbara , Phosphorodiamidate Morpholino Oligomer , Leo Vartorella , Deborah Elson Matthew Deyoung , Glenn Noronha , Kennethc Swan , University College London , Casey Eye Institute , University Of Florida Medical School , Baylor College Of Medicine , American Geriatrics Society , Ear Infirmary At Harvard Medical School , Foundation Fighting Blindness Scientific Advisory Board , Ocular Tissue Engineering Laboratory , Drug Administration , Research To Prevent Blindness ,

PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U.S. Expansion in First Quarter Update

Share this article
Share this article
NEW YORK and PERTH, Australia, April 30, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced a first quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones.
PYC has had an exciting quarter of progress against our Company objectives. We have achieved continued validation of our PPMO technology in our lead candidate VP-001 for retinitis pigmentosa type 11, further development of our ocular pipeline as well as PYC s first set of preclinical data from our CNS discovery efforts demonstrating superior delivery of RNA therapeutic throughout the brain and spinal cord. The potential of our pioneering PPMO technology is vast and we look forward to advancing this technology to provide solutions for patients with inherited o ....

Western Australia , Michael Rosenblatt , Phosphorodiamidate Morpholino Oligomer , Kaggen Ausma , Sahm Nasseri , Leo Vartorella , Deborah Elson Matthew Deyoung , Glenn Noronha , Drug Administration , Executive Officer , Alan Tribe , Ocular Diseases , Investigational New Drug , Nervous System , Chief Development Officer , Chief Business Officer , Board Directors , Jason Haddock , West Coast , Adeno Associated Virus , Mol Ther Methods Clin , Global Burden , Disease Study , Pyc Therapeutics , மேற்கு ஆஸ்திரேலியா , மைக்கேல் ரோசன்ப்ளாட் ,

PYC Therapeutics Expands U.S. Executive Leadership Team with the Appointment of Glenn Noronha, PhD, as Chief Development Officer

Share this article
Share this article
PERTH, Australia and NEW YORK, Feb. 23, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Glenn Noronha, PhD, as Chief Development Officer. Dr. Noronha will oversee the Company s translational clinical development, regulatory, manufacturing and preclinical development activities as it advances its pipeline of multiple drug candidates which is initially focused on inherited ocular diseases.
Dr. Noronha brings to PYC over 20 years of progressive leadership and research experience across both small and large biotechnology and pharmaceutical companies, with deep expertise in development of ophthalmology drug candidates, through his positions at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the ophthalmology subsidiary of Novartis. He has a proven tra ....

United States , Western Australia , Bio Pharma , Navire Pharma , Los Angeles , Deborah Elson Matthew Deyoung , Sahm Nasseri , Leo Vartorella , Glenn Noronha , Development Officer , University Of California , Drug Administration , Jw Theriac Pharmaceuticals , Chief Development , Bridgebio Pharma , Clearside Biomedical , New Drug , Drug Applications , Investigational New Drug , Executive Officer , Chief Scientific Officer , Fortify Therapeutics , Retinagenix Therapeutics , Translational Medicine , Vice President , Sucampo Pharma Americas ,